Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

CD31 + Cell Enrichment Enhances Therapeutic Effects of Stromal Vascular Fraction in Experimental Primary Osteoarthritis: A Preclinical Study in the Dunkin Hartley Guinea Pig Model.

Zhou S., Winkler T., Chen B., Grzeski M., Yang Y., Fleckenstein FN.

Laboratory Study on Osteoarthritis, Cartilage Damage, Immune Modulation, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Adv Sci (Weinh) (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
42435424
DOI
10.1002/advs.76187

Abstract (original English)

Despite the growing burden of osteoarthritis (OA), effective disease-modifying treatments remain limited. Hyaluronic acid, platelet-rich plasma, and hydrogels are in clinical use, but their efficacy beyond placebo is debated. Cell-based therapies are continuously investigated for their disease-modifying potential. Stromal vascular fraction (SVF), a minimally processed and clinically accessible cell product, has shown therapeutic potential, but remains poorly characterized in respect to its pro-regenerative cell types and molecular signaling. To determine whether CD31 + cell enrichment enhances the regenerative efficacy of SVF, a comparative efficacy study was conducted using the Dunkin Hartley guinea pig model of spontaneous OA. Spatial proteomics reveals that both treatments modulate cartilage extracellular matrix (ECM) composition, reducing fibronectin and COL1A1 levels, with CD31 + SVF showing more pronounced effects. Both therapies attenuate cartilage fibrosis, increase aggrecan, suppress MMP-13, and reduce TNF-α and MCP-1 expression. Compared to SVF, CD31 + SVF shows greater and more consistent improvements in subchondral and trabecular bone integrity. These findings demonstrate that CD31 + enrichment enhances the therapeutic potential of SVF, likely through more consistent modulation of ECM remodeling and osteochondral integrity. Our results provide a preclinical rational

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research